Tolerability of treatment: withdrawal for medical reasons · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in tolerability of treatment: withdrawal for medical reasons compared with placebo: all studies (low certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ All studies objective compared with placebo according to any definition (low certainty).
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
Dropout ‐ Studies with low risk of bias · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ Studies with low risk of bias compared with placebo according to any definition (high certainty).
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout compared with placebo (moderate certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with major depression
Antidepressants plus benzodiazepines showed no clear difference in acceptability of treatment (dropout for any reason) compared with antidepressants alone (moderate certainty).
1 finding from 1 review
Anxiety · patients with major depression
1 finding from 1 review
Adverse effects (dropouts) · patients with major depression
Antidepressants plus benzodiazepines probably leads to lower adverse effects (dropouts) compared with antidepressants alone (moderate certainty).
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes depression: meeting study criteria for depression at end treatment… compared with placebo (very low certainty).
1 finding from 1 review
Scoring above cut‐off points for a depressive disorder at end of treatment (Analysis 1.2) · people with stroke
1 finding from 1 review
Depression: mean scores at end of treatment (Analysis 1.4) · people with stroke
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Depressive symptoms · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).
1 finding from 1 review
Response to treatment ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found